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Background: The synergistic interactions between pharmacotherapy and pulmonary rehabilita-
tion has been provided, but it remains to be established whether this may also apply to more
severe patients.
Objectives: We have examined whether tiotropium enhances the effects of exercise training in
patients with advanced COPD (FEV1 60% predicted, hypoxemia at rest corrected with oxygen
supplementation, and limitations of physical activity).
Methods: We enrolled 22 patients that were randomised to tiotropium 18 mg or placebo inha-
lation capsules taken once daily. Both groups (11 patients in each group) underwent an in
patient pulmonary rehabilitation program and were under regular treatment with salmeter-
ol/fluticasone twice daily. Each rehabilitation session was held 5 days per week (3 h/day)
for a total of 4 weeks.
Results: Compared to placebo, tiotropium had larger impact on pulmonary function
(FEV1þ 0.164L, FVC þ0.112L, RV 0.544L after tiotropium, FEV1þ 0.084L, FVC 0.039L, RV
0.036L after placebo). The addition of tiotropium allowed a longer distance walked in
6 min (82.3 m vs. 67.7 m after placebo) and reduced dyspnoea (Borg score) (0.4 vs. þ0.18
after placebo) when compared with baseline (pre pulmonary rehabilitation program). The
changes in SGRQ from baseline to the end of treatment were: total score 28.3U, activity
27.8U, impact 14.5U, and symptoms 33.4U in the placebo group; and total score
19.1U, activity 18.9U, impact 16.4U, and symptoms 33.8U in the tiotropium group.ento di Medicina Interna, Universita` di Roma Tor Vergata, Via Montpellier 1, 00133 Roma, Italy.
iroma2.it (M. Cazzola).
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Triple therapy and pulmonary rehabilitation 413Conclusions: Our study clearly indicates that there is an advantage in combining pulmonary
rehabilitation with an aggressive drug therapy in more severe patients.
ª 2009 Elsevier Ltd. All rights reserved.Table 1 Basic anthropometric data of the studied
population.
Without
tiotropium
With
tiotropium
Sex (M/F) 10/1 9/2
Age (yrs) 69.82 3.12 70.00 2.11
Height (cm) 168.9 1.8 169.6 1.9
Duration of COPD (yrs) 21.36 4.00 14.36 3.82
BMI 24.82 1.33 25.91 0.91
BODE 4.46 0.47 3.36 0.53
FEV1 (% predicted) 41.55 3.09 51.73 2.81
PaO2 (mmHg) 55.33 0.95 57.03 1.02
Values are mean SE.Introduction
Patients with chronic obstructive pulmonary disease (COPD)
often complain of exercise intolerance. Despite the tradi-
tional belief that exercise is primarily limited by the
inability to adequately increase ventilation to meet
increased metabolic demands in these patients, significant
deficiencies in muscle function, oxygen delivery and
cardiac function are observed that contribute to exercise
limitation. This means that exercise intolerance in COPD is
complex and multifactorial and implies that, in order to
reach optimal status, an array of interventions will be
necessary.1
Pulmonary rehabilitation is designed to reverse these
exerciselimiting factors through supervised exercise
training, respiratory care, and education.2 It is defined as
‘‘a multidisciplinary program of care for patients with
chronic respiratory impairment that is individually tailored
and designed to optimize physical and social performance
and autonomy’’.3 In fact, a rather recent metaanalysis
found statistically significant improvements in all the
examined outcomes.4
There is now evidence that pulmonary rehabilitation of
patients with COPD is more effective when the optimal
bronchodilation has been reached.1 Bronchodilators play
a central role in patients with COPD.5 They have been
shown to improve airflow limitation but, unfortunately,
have an inconsistent effect on various measures of exercise
capacity.5 In fact, leg fatigue will prevent patients with
COPD from obtaining full advantage of bronchodilation, but
muscle fatigue can be improved with exercise training.1 It
was not surprising, therefore, that the benefits of rehabil-
itative exercise were amplified when participants received
the longacting anticholinergic agent tiotropium6 and it
was suggested that the relatively modest improvements in
healthrelated quality of life and exercise tolerance seen
when bronchodilators are administered will be amplified
when combined with pulmonary rehabilitation.7
Since Casaburi et al.6 enrolled patients with moderate
COPD, it remains to be established whether their findings
may also apply to more severe patients. Therefore, we
aimed to examine whether tiotropium enhanced the effects
of exercise training also in patients with advanced COPD
(FEV1 60 predicted, hypoxemia at rest corrected with
oxygen supplementation, and limitations of physical
activity), who were under regular treatment with salme-
terol/fluticasone.
Patients and methods
Considering that physical activity is reduced in patients
with COPD from GOLD II/BODE 1 and clinical characteristics
of patients with COPD only incompletely reflect their
physical activity,8 we enrolled 22 inpatients suffering
from advanced COPD (FEV1 60 predicted, hypoxemia atrest corrected with oxygen supplementation, and limita-
tions of physical activity). All were exsmokers. They were
capable of performing a walking test. Patients with overt
comorbidity preventing them from safely performing an
exercise test could not participate in this trial. In partic-
ular, patients did not suffer from cardiovascular, neuro-
logical disorders or advanced osteoarthrosis. Table 1
illustrates basic anthropometric data of the studied pop-
ulation. All trial procedures were conducted according to
the Declaration of Helsinki and the protocol was approved
by an independent ethics committee.
All patients were randomised to tiotropium 18 mg or
placebo inhalation capsules taken once daily to be inhaled
at 8 AM. Both groups (11 patients in each group) underwent
an inpatient pulmonary rehabilitation program. All were
under regular treatment with salmeterol/fluticasone 50/
500 mg twice daily from at least one month. The in-patients
pulmonary rehabilitation program included the following:
exercise and muscle training (upper and lower extremity
endurance training, respiratory muscle training and
stretch); mucus evacuation techniques; disease education;
psychosocial intervention; instruction in the use of medi-
cation; and relaxation techniques. Each session was held 5
days per week (3 h/day) for a total of 4 weeks.
Functional tests were conducted at the initial screening
(visit 1); randomization (visit 2), which served as the
baseline measurement, and after 4 weeks of treatment
(visit 3) 24 h after the last inhalation of tiotropium and 12 h
after the last inhalation of salmeterol/fluticasone. Lung
function tests were performed using a body plethysmo-
graph (Masterlab, Jaeger, Wurzburg, Germany) according to
the current recommendations of the ATS/ERS Task Force on
standardisation of pulmonary function tests.9e11
Also the 6 min walking tests (6MWT) were performed at
the initial screening (visit 1), randomization (visit 2), which
served as the baseline measurement, and after 4 weeks of
treatment (visit 3). They were conducted in an enclosed
corridor on a flat course 30 m in length according to the
procedures recommended by the American Thoracic
Table 2 Changes in pulmonary function from baseline. All values are mean SE. NS, p not significant vs. pre pulmonary
rehabilitation (PR) program.
FEV1 FVC IC TLC VR
Without tiotropium
Before PR 1.145 0.089 2.500 0.128 2.310 0.262 6.553 0.747 3.779 0.507
After PR 1.229 0.132
pZ 0.354
NS
2.461 0.149
pZ 0.701
NS
2.056 0.131
pZ 0.355
NS
6.672 0.316
pZ 0.816
NS
3.743 0.373
pZ 0.899
NS
With tiotropium
Before PR 1.419 0.093 2.811 0.144 2.282 0.170 6.515 0.426 3.704 0.444
After PR 1.580 0.183
pZ 0.290
NS
2.923 0.201
pZ 0.603
NS
2.399 0.155
pZ 0.468
NS
6.961 0.450
pZ 0.464
NS
3.160 0.338
pZ 0.240
NS
414 F. Pasqua et al.Society (ATS).3 To avoid interference with the patients’
exercise performance, patients walked unaccompanied and
no encouragement was given. Oxygen saturation (SpO2) and
heart rate (HR) were recorded continuously by pulse oxi-
metry (Pulsox 5 portable pulse oximeter; Minolta, Tokyo,
Japan). At the end of the walking tests, the participant was
told to stop, and total distance covered was calculated to
the nearest metre. Assessment for the level of dyspnoea
was carried out via the Borg CR10 scale12 that was proposed
by the same staff member who ensured full comprehension
on the part of the patient.6MWT
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Figure 1 Changesin distance walked in 6 min (6MWT) and in
the exerciseinduced dyspnoea (Borg score) from baseline.
Values are mean SE. *p< 0.05, ***p< 0.001 vs. pre pulmonary
rehabilitation (PR) program.Healthrelated quality of life was determined using the
St. George’s respiratory questionnaire (SGRQ) and was
explored at each visit.
Thiswas a pilot study and the first known evaluation of the
additive effect of tiotropium on a combination of salme-
terol/fluticasone and pulmonary rehabilitation in patients
with advanced COPD. In view of the lack of previous experi-
ences, no statistical hypotheses were drawn and conse-
quently no formal sample size calculationwasmade. The use
of a pilot study such as the current study in clinical research is
awellestablished scientific procedure and only through the
use of a pilot study can statisticians clarify data distributions
and determine appropriate sample sizes for fullscale clin-
ical trials.13
Student’s t-test for paired data and repeated ANOVA
measurements were used for statistical analysis. Values of
p< 0.05 were considered as significant.
Results
Compared to placebo, tiotropium had larger impact on
pulmonary function at the visit 3 (FEV1þ 0.164L, FVC
þ0.112L, RV 0.544L after tiotropium, FEV1þ 0.084L, FVC
0.039L, RV 0.036L after placebo), although all differ-
ences were statistically non significant when compared
with basal values (Table 2).
The addition of tiotropium allowed a longer distance
walked in 6 min (82.3 m vs. 67.7 m after placebo) and
reduced dyspnoea (Borg score) (0.4 vs.þ 0.18 after
placebo); all differences, but not the change in Borg score
after tiotropium, were statistically significant when
compared with basal values (pre pulmonary rehabilitation
program) (Fig. 1; Table 3).
The changes in SGRQ from baseline to the end of
treatment were: total score 28.3U, activity 27.8U,
impact 14.5U, and symptoms 33.4U in the placebo
group; and total score 19.1U, activity 18.9U, impact
16.4U, and symptoms 33.8U in the tiotropium group.
Almost all changes were statistically significant when
compared with the baseline values (Table 4).
Discussion
In the present study, we have observed that pulmonary
rehabilitation led to an improvement in lung function in
Table 3 Changes in Borg score and SpO2 from baseline. All values are mean SE. *p< 0.05, NS p not significant vs. pre
pulmonary rehabilitation (PR) program.
SpO2 before
6MWT (%)
SpO2 at the end of
6MWT (%)
Dyspnea (Borg score)
before 6MWT
Dyspnea (Borg score)
at the end of 6MWT
Without tiotropium
Before PR 96.45 0.28 94.00 0.43 0.18 0.12 2.09 0.21
After PR 96.18 0.35
pZ 0.277
NS
93.27 0.41
pZ 0.038
*
0.36 0.15
pZ 0.167
NS
1.91 0.21
pZ 0.167
NS
With tiotropium
Before PR 96.27 0.33 94.18 0.60 0.36 0.15 1.73 0.36
After PR 96.64 0.34
pZ 0.476
NS
93.36 0.43
pZ 0.260
NS
0.19 0.14
pZ 0.167
NS
1.73 0.24
pZ 1.000
NS
Triple therapy and pulmonary rehabilitation 415many patients and the addition of tiotropium amplified this
effect, although its impact was not statistically significant.
It is likely that the lack of statistical significance is related
to the lack of statistical power of our sample. Obviously,
there was a possibility of a type II error, which supported
the lack of significance that we have repeatedly observed14
and, perhaps, a study with a larger sample would likely
have reached statistical significance. We know that the
relatively small sample of patients enrolled in this study
could be regarded as a limitation, but again we must
highlight that this study was conducted in a single centre as
a pilot investigative trial designed only to examine if in
patients suffering from more severe forms of COPD the
combined treatment with pulmonary rehabilitation and
a triple pharmacological therapy might have an advantage.
In any case, it has been documented that, in general,
pulmonary rehabilitation does not affect lung function.15
Recently, Ambrosino et al.,16 who explored whether
tiotropium was able to enhance the effects of exercise
training in patients with COPD and a FEV1 60% of pre-
dicted, reported that tiotropium significantly increased
trough FEV1 compared to placebo (adjusted mean differ-
ences between groups: 0.100 0.05L on test week 4;
pZ 0.047) Tiotropium also increased trough FVC compared
to placebo (adjusted mean differences between groups:
0.124 0.061L, on test week 4; pZ 0.044). There is no
doubt that the trend that we have observed in our patients
is similar to that reported by Ambrosino et al.16 It should be
stressed, however, that the improvement that we have
observed was obtained in patients under a regularTable 4 The changes in SGRQ from baseline. All values are mea
vs. pre pulmonary rehabilitation (PR) program.
Overall Activity
Without tiotropium
Before PR 45.45 5.86 56.36 5.1
After PR 17.18 3.28
pZ 0.0024**
28.55 3.5
pZ 0.0007*
With tiotropium
Before PR 45.73 5.79 61.09 7.4
After PR 26.64 6.98
pZ 0.0068**
42.18 8.3
pZ 0.0098*treatment with salmeterol/fluticasone, which can by itself
lead to an improvement in respiratory function in patients
with advanced COPD,17 and this might be another justifi-
cation for the failure to reach statistical significance in our
trial.
What is worthy of particular note is the fact that we
observed a significant increase in the distance walked in
the group treated with pulmonary rehabilitation plus the
addition of salmeterol/fluticasone, and a further increase
when patients were treated also with tiotropium. This
finding contrasts with the observation of Ambrosino et al.16
that the addition of tiotropium to pulmonary rehabilitation
did not improve the 6MWT.
Our data showed that a treatment with pulmonary
rehabilitation plus salmeterol/fluticasone twice daily
allowed not only to reach the minimal clinical significance
limit (52 m) proposed by Troosters et al.,18 but also to
obtain a significant change in Borg score for dyspnoea
induced by the 6MWT when compared with the
pretreatment values. Intriguingly, the addition of tio-
tropium increased the distance walked without influencing
the Borg score. This is not a real surprise because pulmo-
nary rehabilitation relieves dyspnoea and fatigue, improves
emotional function and enhances patients’ control over
their condition in a moderately large and clinically signifi-
cant manner,19 and, consequently, it is likely that the
addition of a bronchodilator is not perceived a further aid.
Our findings differ from that of Ambrosino et al.16 also
with respect to their observation that tiotropium in
combination with pulmonary rehabilitation significantlyn SE. *p< 0.05, **p< 0.01, ***p< 0.001, NS p not significant
Impacts Symptoms
7 36.82 6.92 53.64 8.15
7
**
13.00 3.12
pZ 0.0127*
20.18 5.55
pZ 0.0008***
5 37.36 5.68 44.64 8.18
7
*
22.73 8.37
pZ 0.0811 NS
10.82 3.46
pZ 0.0021**
416 F. Pasqua et al.improved dyspnoea but did not show any additional benefit
induced by the pulmonary rehabilitation in exercise toler-
ance, as measured by the 6MWT. Ambrosino et al.16 sug-
gested that the modest improvement in exercise capacity
to either pulmonary rehabilitation or tiotropium observed
in their study likely related to methodological issues,
including the choice of the functional measurement of
endurance. In effect, recent research has been suggested
that the 6MWT test may not be as responsive to broncho-
dilation as the endurance shuttle walk.20
We recognise that 6MWT is not physiologically pure
because it is selfpaced and, unless appropriately con-
ducted, may be subject to learning and motivation
effects.21 Furthermore, it is a physiological hybrid test that
may produce erratic metabolic demand that may include
peak or endurance performance.3 Nonetheless, the 6MWT is
probably the most popular investigation because of its
simplicity, relevance to daily life, widespread use and
availability of reference values and, in any case, we
documented that 6MWT seems to be an appropriate
instrument for assessing the exercise response to a bron-
chodilator in COPD.22
It is much more likely that the lack of efficacy of tio-
tropium in combination with pulmonary rehabilitation on
exercise tolerance as measured by the 6MWT reported by
Ambrosino et al.16 was due to the variability in the conduct
of the test due to the enrolment of multiple sites with
variable experience. Another explanation might be the fact
that in the Ambrosino’s study,16 at baseline patients had
a relatively well preserved 6MWT (mean >400 metres),
whereas in our study, focused on more severe patients with
documented limitations of physical activity, the mean
baseline value was 310 metres. Whatever the case may be,
it must be mentioned that, apparently, there is a larger
room for improvement in 6MWT in hypoxemic than in
non-hypoxemic patients.23
What our study confirms looking at the Ambrosino’s
paper16 is that pulmonary rehabilitation improves health
related quality of life as it is expressed by the SGRQ and the
addition of tiotropium does not bring further improvement.
This was not an unexpected finding because it is well known
that pulmonary rehabilitation results in greater improve-
ments in important domains of healthrelated quality of
life and functional exercise capacity when compared with
other important modalities of care for patients with COPD
such as inhaled bronchodilators or theophylline.24,25 In any
case, we must mention that we observed surprising large
changes in the different domains of the SGRQ that can only
be justified considering the population included in the trial.
In conclusion, our study, despite its limitations, suggests
that there is an advantage in combining pulmonary reha-
bilitation with an aggressive drug therapy in more severe
patients. This is not a real surprise considering that the
present prospective is to use a triple therapy in patients
with more advanced COPD.26,27 As mentioned before, the
failure to achieve the statistical significance in changes in
some parameters is likely due to the lack of statistical
power in the study, although it is possible that the inclusion
of outcomes with different construct may lead to responses
that are not always relevant because the construct of
a specific outcome might not be really influenced by the
treatment. In effect, although some outcomes have beenshown to change with therapy, their observed changes are
not always reflected by changes in traditional measures of
disease severity such as FEV1. This is because other path-
ophysiological (e.g. dynamic hyperinflation of the lungs)
and psychological (e.g. coexisting anxiety) influences also
affect these outcomes.28 Obviously, the results of this pilot
study will aid planning for further largescale confirmatory
studies.
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